Alpha Tau Medical has received IRB approval from IRST (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), in Italy for clinical trials with its Alpha DaRT (Diffusing Alpha–emitters Radiation Therapy) technology for the treatment of Squamous Cell Carcinoma (SCC) in skin cancer.
The company is also in the process of finalizing additional protocols for clinical trials in Colorectal and Prostate cancers. Initial trials are due to start within the next few months.
Alpha DaRT technology enables the possibility of providing a local alpha-radiotherapy treatment based on alpha emitters, and has several advantages:
Highly Potent and Ultra conformal
Effective regardless of tumor oxygen level
Short half-life – quick clinical results
Negligible gamma radiation, no special shielding equipment is needed
Disposable product – not capital equipment is needed
To keep up to date on our progress in the clinical trials, please follow us on LinkedIn https://www.linkedin.com/company/10538741 , Twitter https://twitter.com/AlphaTauMedical or subscribe to our newsletter.
